Founded in 1985, Medis draws on the development and manufacturing capabilities of its parent company Actavis, whose R&D specialists maintain a strong development pipeline. Our 25 years' experience and in-depth understanding of the generics sector make us particularly attractive to customers around the world.
A wide choice
Medis offers a wide portfolio of quality products and intellectual property to pharmaceutical companies. We provide generic pharmaceutical products for human use, mainly in the form of tablets, capsules and injections. Now featured in our comprehensive portfolio is a growing range of specialist oncology products.
Pleased to be of service
With offices located in Iceland, Germany, France and the UK (Isle of Man), and numerous regional managers and business development support elsewhere, Medis provides services and products to most European nations and has marketing authorisations in many other countries worldwide. We are increasingly serving the needs of customers in fast expanding markets such as the Middle East, Russia, Spain, Poland, South America and Asia, including Japan.
Here at Medis, we are dedicated to service excellence and the provision of high quality intellectual property. For all customer service, including sales orders or related matters, please contact our head office in Iceland.
Fast access to new products
Medis has a solid track record of securing regulatory approval prior to patent expiries and obtaining marketing authorisations the world over. Our vast experience in launching new products and our proven regulatory skills contribute to a highly successful approach, which gets results fast.
State-of-the-art production
Growing demand for Medis supplies is being met via our manufacturing contracts with Actavis. We work with state-of-the-art EU-GMP approved sites, primarily in Europe, and have access to 15 production facilities, which provide capacity for 21 billion tablets per annum.